Stock Titan7/10/2026Neutral (0.134)
Crinetics Pharmaceuticals (CRNX) sets 1-year executive non-competes tied to Vertex deal
Crinetics Pharmaceuticals has established one-year non-compete agreements with four key executives in connection with its upcoming merger with Vertex Pharmaceuticals. These agreements, effective post-merger, restrict the executives from working for competing businesses in Crinetics' operating territories. In exchange, CFO Tobin Schilke will receive $140,000, while Chief Scientific Officer Stephen Betz and Chief Commercial Officer Isabel Kalofonos will each receive $30,000 upon the merger's closing.
